Novartis is highlighting results from a phase III study that has investigated the efficacy and safety of Lu-177 PSMA-617, a radioligand therapy for patients with prostate-specific membrane antigen (PSMA)-positive metastatic prostate cancer.
Phase III of the VISION trial found that Lu-177 PSMA-617 improved overall survival and radiographic progression-free survival in patients with PSMA-positive metastatic castration-resistant prostate cancer, according to Novartis.
Radioligand therapy consists of a targeting compound that attaches to tumor markers and a radioactive isotope, both of which inhibit tumor growth, the company said.
